How much cash does LB Pharmaceuticals Inc Common Stock generate?

LB Pharmaceuticals Inc Common Stock (LBRX) generated -$55.2M in operating cash flow over the trailing twelve months.

What is LB Pharmaceuticals Inc Common Stock's free cash flow?

After $331.0K of capital expenditures, LB Pharmaceuticals Inc Common Stock's free cash flow was -$55.5M over the trailing twelve months.

Where does LB Pharmaceuticals Inc Common Stock's cash flow data come from?

Every line is extracted from LB Pharmaceuticals Inc Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

LB Pharmaceuticals Inc Common Stock LBRX Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$38.95M-54.5%	-$25.2M-34.0%	-$18.8M+36.1%	-$29.43M+43.6%	-$52.19M+17.3%
Depreciation and amortization	——	——	——	——	——
Stock-based compensation	——	——	——	——	——
Gain (loss) on sale of assets	——	——	——	——	——
Change in accounts payable	——	——	——	——	$868K-82.7%
Change in other assets	——	——	——	——	$1.23M-29.7%
Change in operating lease liabilities	——	——	——	——	-$43K+28.3%
Net cash from operating activities	——	——	——	——	——
Capital expenditures	——	——	——	——	——
Proceeds from maturities/sales of investments	——	——	——	——	——
Net cash from investing activities	——	——	——	——	——
Payment of debt issuance costs	——	——	——	——	——
Proceeds from issuance of preferred stock	——	——	——	——	——
Net cash from financing activities	——	——	——	——	$28.74M-25.0%
Net increase (decrease) in cash	——	——	——	——	——
Income taxes paid	——	$1K0.0%	$1K0.0%	$1K0.0%	$1K0.0%
Accretion (Amortization) of Discounts and Premiums, Investments	——	——	——	——	——
Depreciation	——	——	——	——	——
Gain (Loss) on Sale of Investments	——	——	——	——	——
Operating lease liabilities	——	——	——	——	-$43K+28.3%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	$1.23M-29.7%
Satisfaction of management and incentive fees in stock	——	——	——	——	——
Non Cash Lease Expense	——	——	——	——	——
Write Off Of Property And Equipment	——	$8K+33.3%	$6K+50.0%	$4K+100%	$2K—
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	——	$2.5M-73.4%	$9.4M-42.3%	$16.3M-29.7%	$23.2M-22.9%
Sale of investments	——	$2.5M-67.9%	$7.79M-40.4%	$13.08M-28.8%	$18.36M-22.4%
Proceeds from maturities of investments	——	——	——	——	——
Payment Of Issuance Costs For Private Placement	——	——	——	——	——
Payments Of Stock Issuance Costs	——	——	——	——	——
Net proceeds from sales of subsidiary shares	——	$327.75M+33.3%	$245.81M—	——	——
Common stock issuance for private placement	——	——	——	——	——
Proceeds From Warrant Exercises	——	——	——	——	$17.25K-25.0%
Acquisition Of Leasehold Improvements	——	$0-100%	$289.5K-50.0%	$579K-33.3%	$868.5K-25.0%
Exchange Offer (Note 12)	——	$114.26M+33.3%	$85.7M—	——	——
Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments	——	——	——	——	——
Increase Decrease In Operating Lease Liability	——	——	——	——	-$43K+28.3%
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	——
Write Off Of Deferred Debt Issuance Cost	——	——	——	——	——
Free cash flow	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does LB Pharmaceuticals Inc Common Stock generate?: LB Pharmaceuticals Inc Common Stock (LBRX) generated -$55.2M in operating cash flow over the trailing twelve months.
What is LB Pharmaceuticals Inc Common Stock's free cash flow?: After $331.0K of capital expenditures, LB Pharmaceuticals Inc Common Stock's free cash flow was -$55.5M over the trailing twelve months.
Where does LB Pharmaceuticals Inc Common Stock's cash flow data come from?: Every line is extracted from LB Pharmaceuticals Inc Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.